GlassScriptPhysician profile
Sophia Rahman
NPI 1306142955
$3,074.01
in general payments reported to CMS, 2019-2025
34 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,376 · 2020: $292 · 2021: $651 · 2022: $158 · 2023: $397 · 2024: $94.56 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.54 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $650.58 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Abbvie INC. | $285.45 | 2019-2024 | |
| Amarin Pharma, INC. | $284.97 | 2019-2021 | |
| Glaxosmithkline, LLC. | $241.97 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $228.60 | 2020-2024 | Emgality, Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $175.78 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.05 | 2019 | |
| Eyepoint US, INC. | $103.48 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.66 | 2023 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $97.61 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $86.47 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $84.85 | 2019-2023 | Farxiga |
| Astellas Pharma US INC | $76.06 | 2019-2024 | Myrbetriq, Veozah |
| Allergan, INC. | $60.08 | 2019-2020 | |
| Medtronic, INC. | $56.45 | 2021-2025 | Intellis Adaptivestim |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $55.17 | 2020-2021 | |
| Pfizer INC. | $47.92 | 2022-2023 | |
| Exact Sciences Corporation | $30.80 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.64 | 2019-2020 | |
| Bardy Diagnostics, INC. | $24.84 | 2022 | |
| Arbor Pharmaceuticals, INC. | $24.69 | 2019 | |
| Coloplast Corp | $21.62 | 2019 | |
| Advanced Accelerator Applications | $21.19 | 2019 | |
| Genzyme Corporation | $21.19 | 2020 | |
| Medtronic Vascular, INC. | $20.43 | 2020 | |
| Nestle Healthcare Nutrition INC. | $17.86 | 2021 | |
| Eisai INC. | $17.17 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.54 | 2020 | |
| Amgen INC. | $15.28 | 2024 | Otezla, Repatha |
| Ibsa Pharma INC. | $15.08 | 2019 | |
| Boston Scientific Corporation | $14.72 | 2025 | General - Female Sui |
| E.R. Squibb & Sons, L.L.C. | $12.81 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sophia Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.